Influence of age and subtype in outcome of operable liposarcoma.


Journal

La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 13 02 2018
accepted: 02 11 2018
pubmed: 14 11 2018
medline: 27 4 2019
entrez: 14 11 2018
Statut: ppublish

Résumé

Liposarcoma (LPS) is rare tumor deriving from adipocytes. LPS is classified into histological subtypes: well-differentiated (WDLPS), dedifferentiated (DDLPS), myxoid (MLPS) and pleomorphic (PLPS). A tailored approach taking into account the specificity of disease subtype and age at presentation could be helpful in delineating therapeutic management of liposarcoma. In this paper, we report a retrospective series of a single-institution cohort of patients with LPS, undergoing surgery and radiotherapy and/or chemotherapy. The aim of this study is to evaluate whether clinical characteristics, tumor- and treatment-related features affect clinical outcome in patients treated with curative intent for non-metastatic liposarcoma. Data of patients with locally advanced, non-metastatic liposarcoma treated between 1990 and 2015 were retrospectively reviewed. Data about patient, tumor and treatment features were collected. Two patients subgroups were identified according to age (cutoff: age < 65 years or > 65 years). Statistical analysis was performed to assess correlation between the above-cited variables and local recurrence-free survival (DFS-LR), distant metastasis-free survival, overall survival (OS) and disease-specific survival (DSS); moreover, differences in clinical outcome between the two age groups were identified. Data of 186 patients were collected. At diagnosis, 27.4% of patients were 65 years or older. At a median follow-up of 8.6 years (range 0.1-27.3 years), Kaplan-Meier (KM) survival analysis showed that LR, DM, OS and DSS were 75.5%, 76.6%, 48.1% and 72.1%, respectively. KM analysis showed that age > 65, DDLPS and lower limb localization were related to LR (p = 0.001, p = 0.0001 and p = 0.0001, respectively). Association between LR, age and DDLPS persisted both at univariate (p = 0.003 and p = 0.0001, respectively) and multivariate Cox regression (CR) analysis (p = 0.024 and p = 0.002). Age, tumor depth and grading influenced distant recurrence, both at KM (p = 0.023, p = 0.026 and p = 0.016) and univariate CR (p = 0.026, p = 0.042 and p = 0.012). Age and grading were confirmed at multivariate analysis (p = 0.009 and p = 0.017). Patients with WDLPS and wide excision had significantly better OS (p = 0.001 and p = 0.03, respectively), while histological G3 and age > 65 were related with worse OS (p = 0.008 and p = 0.0001, respectively). Age, DDLPS and grade were related to OS at univariate (p = 0.0001, p = 0.0001 and p = 0.03, respectively) and multivariate CR analysis (p = 0.031, p = 0.0001 and p = 0.001, respectively). However, analyzing the specific causes of death, female died less often for tumor-related causes, with a DSS of 91.0% compared to 57.4% of male counterpart (p = 0.005). At Kaplan-Meier analysis, postoperative radiotherapy resulted in a statistically significant better disease-specific survival than postoperative radiotherapy (82.9% vs. 46.2%, p = 0.045). High grade correlated with poorer disease-specific survival (59.3%) than intermediate and low grade (73.4% and 91.6%, respectively) (p = 0.008). Association between DSS, sex and grade persisted both at univariate (p = 0.008 and p = 0.022, respectively) and multivariate Cox regression (CR) analysis (p = 0.014 and p = 0.038). Histotype-driven schedules of treatment should be developed to take into account biological heterogeneity of this disease. Further studies are needed to stratify patients subgroup and develop tailored treatment strategies (i.e., altered fractionations and different chemotherapy regimens in aggressive subtypes), in particular more prospective trials are needed to develop treatment guidelines in elderly STS, taking into account the frailty and the peculiarity of this subgroup.

Identifiants

pubmed: 30421387
doi: 10.1007/s11547-018-0958-4
pii: 10.1007/s11547-018-0958-4
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

290-300

Références

Adv Anat Pathol. 2016 Jan;23(1):30-40
pubmed: 26645460
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Ann Oncol. 2014 Jun;25(6):1222-8
pubmed: 24608201
Ann Surg. 2004 Oct;240(4):686-95; discussion 695-7
pubmed: 15383796
BMC Cancer. 2009 Jun 26;9:205
pubmed: 19558664
J Clin Oncol. 2011 Oct 20;29(30):4029-35
pubmed: 21931025
Cancer. 2009 Jul 15;115(14):3254-61
pubmed: 19472403
Radiol Med. 2014 Mar;119(3):195-200
pubmed: 24277509
Eur J Surg Oncol. 2015 Jul;41(7):899-904
pubmed: 25659772
Lancet. 2002 Jun 29;359(9325):2235-41
pubmed: 12103287
J Clin Oncol. 1996 May;14(5):1679-89
pubmed: 8622088
Am J Surg Pathol. 1997 Mar;21(3):271-81
pubmed: 9060596
Am J Surg Pathol. 2004 Oct;28(10):1257-67
pubmed: 15371941
J Clin Oncol. 2018 Jan 10;36(2):151-159
pubmed: 29220294
Mol Cancer Res. 2008 Oct;6(10):1575-81
pubmed: 18922973
J Clin Oncol. 1998 Jan;16(1):197-203
pubmed: 9440743
Cancer. 2006 Nov 15;107(10):2455-61
pubmed: 17036354
Hematol Oncol Clin North Am. 2013 Oct;27(5):939-55
pubmed: 24093169
Ann Surg Oncol. 2007 Apr;14(4):1507-14
pubmed: 17252290
Ann Surg. 2006 Sep;244(3):381-91
pubmed: 16926564
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):760-5
pubmed: 17892916
J Surg Oncol. 2002 Jun;80(2):89-93
pubmed: 12173385
Cancer. 2009 Jun 15;115(12):2744-54
pubmed: 19396819
Jpn J Clin Oncol. 2017 May 1;47(5):422-429
pubmed: 28201801
Ann Surg Oncol. 2004 Jan;11(1):78-84
pubmed: 14699038
J Clin Oncol. 1996 Mar;14(3):859-68
pubmed: 8622034
Arch Pathol Lab Med. 2006 Oct;130(10):1448-53
pubmed: 17090186
Ann Oncol. 2010 Dec;21(12):2436-41
pubmed: 20439343
Cancer. 2001 May 15;91(10):1914-26
pubmed: 11346874
J Clin Oncol. 2018 Jan 10;36(2):99-100
pubmed: 29220300
Cancer. 1999 Jan 1;85(1):85-92
pubmed: 9921978
Ann Surg Oncol. 2010 Jul;17(7):1732-8
pubmed: 20354801
Cancer. 2014 Jun 15;120(12):1763-74
pubmed: 24648013
Ann Oncol. 2013 Jul;24(7):1924-30
pubmed: 23493135

Auteurs

Daniela Greto (D)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy. daniela.greto@unifi.it.

Calogero Saieva (C)

Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy.

Mauro Loi (M)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Francesca Terziani (F)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Luca Visani (L)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Pietro Garlatti (P)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Monica Lo Russo (M)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Cristina Muntoni (C)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Carlotta Becherini (C)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Juliana Topulli (J)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Domenico Campanacci (D)

Department of Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.

Giovanni Beltrami (G)

Department of Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.

Guido Scoccianti (G)

Department of Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.

Francesco Muratori (F)

Department of Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.

Pierluigi Bonomo (P)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Isacco Desideri (I)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Giulio Francolini (G)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Lorenzo Livi (L)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50141, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH